Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Uveal Melanoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × gp100 Melanoma Antigen × Dermatologic × Clear all
NCT00960752 2021-08-13

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

M.D. Anderson Cancer Center

Phase 2 Completed
47 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT00085189 2014-05-22

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

University of Southern California

Phase 2 Completed
42 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00303836 2013-06-06

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
58 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡